SFE Investment Counsel Makes New $7.38 Million Investment in Danaher Corporation $DHR

SFE Investment Counsel bought a new stake in Danaher Corporation (NYSE:DHR) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 38,721 shares of the conglomerate’s stock, valued at approximately $7,376,000.

Several other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in Danaher by 1.7% during the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after purchasing an additional 472,608 shares during the last quarter. Capital International Investors increased its position in shares of Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after buying an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 9.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after buying an additional 1,334,221 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Danaher by 11.2% during the 4th quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after buying an additional 1,517,904 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Danaher in the 4th quarter worth about $2,177,106,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.7%

Shares of NYSE:DHR opened at $202.51 on Friday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm has a market cap of $142.37 billion, a price-to-earnings ratio of 35.97, a PEG ratio of 2.52 and a beta of 0.78. The stock’s 50-day moving average price is $193.14 and its two-hundred day moving average price is $193.21. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.77 EPS. On average, research analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on DHR. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. HSBC reduced their price target on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Argus dropped their price objective on shares of Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Finally, Morgan Stanley reduced their target price on Danaher from $270.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.